Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients
Authors:
- Mikaël CroyalMCMikaël Croyal
- Khadija OuguerramKOKhadija Ouguerram
- Maxime PassardMPMaxime Passard
- Véronique Ferchaud-RoucherVFVéronique Ferchaud-Roucher
- Maud ChétiveauxMCMaud Chétiveaux
- Stéphanie Billon-CrossouardSBStéphanie Billon-Crossouard
- Anne-Charlotte de GouvilleAGAnne-Charlotte de Gouville
- Gilles LambertGLGilles Lambert
- Michel KrempfMKMichel Krempf
- Estelle NobécourtENEstelle Nobécourt
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 35 (9) , 2042-2047
Abstract
Objective—: To determine the mechanisms by which extended-release nicotinic acid reduces circulating lipoprotein (a) concentrations in hypertriglyceridemic patients. Approach and Results—: Eight nondiabetic, obese male subjects (aged 48±12 years; body mass index, 31.2±1.8 kg/m 2 ) with hypertriglyceridemia (triglycerides, 226±78 mg/dL) were enrolled in an 8 week, double blind, placebo-controlled cross-over study. At the end of each treatment phase, fasted subjects received a 10 µmol/L per kg bolus injection of [5,5,5- 2 H 3 ]- l -Leucine immediately followed by constant infusion of [5,5,5- 2 H 3 ]- l -Leucine (10 µmol L −1 kg −1 h −1 ) for 14 hours, and blood samples were collected. A liquid chromatography–tandem mass spectrometry method was used to study apolipoprotein (a) (Apo(a)) kinetics. The fractional catabolic rate of Apo(a) was calculated with a single compartmental model using the apolipoprotein B100 (ApoB100) containing very low density lipoprotein tracer enrichment as a precursor pool. Extended-release nicotinic acid decreased plasma triglycerides (−46%; P =0.023), raised high-density lipoprotein cholesterol (+20%; P =0.008), and decreased Apo(a) plasma concentrations (−20%; P =0.008). Extended-release nicotinic acid also decreased ApoB100 (22%; P =0.008) and proprotein convertase subtilisin/kexin type 9 (PCSK9, −29%; P =0.008) plasma concentrations. Apo(a) fractional catabolic rate and production rates were decreased by 37% (0.58±0.28 versus 0.36±0.19 pool/d; P =0.008) and 50% (1.4±0.8 versus 0.7±0.4 nmol/kg per day; P =0.008), respectively. Conclusions—: Extended-release nicotinic acid treatment decreased Apo(a) plasma concentrations by 20%, production rates by 50%, and catabolism by 37%. ApoB100 and PCSK9 concentrations were also decreased by treatment, but no correlation was found with Apo(a) kinetic parameters.Keywords
This publication has 35 references indexed in Scilit:
- HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatmentEuropean Heart Journal, 2013
- Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic miceJournal of Lipid Research, 2012
- Lipoprotein(a) as a cardiovascular risk factor: current statusEuropean Heart Journal, 2010
- Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2010
- National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular DiseaseClinical Chemistry, 2009
- Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing LipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Mechanism of Action of NiacinThe American Journal of Cardiology, 2008
- Effect of Atorvastatin on Apolipoprotein B100 Containing Lipoprotein Metabolism in Type-2 DiabetesThe Journal of Pharmacology and Experimental Therapeutics, 2003
- The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.Journal of Clinical Investigation, 1994
- Protein composition of Lp(a) lipoprotein from human plasmaFEBS Letters, 1983